With no single fresh headline driving attention, Arcellx (ACLX) is drawing interest after a period of strong share price movement. The stock closed at US$114.33 and recorded sizeable gains over the past month and past 3 months.
See our latest analysis for Arcellx.
The recent surge, including a 62.86% 30 day share price return and 78.75% 90 day share price return, sits alongside a 60.15% 1 year total shareholder return and a very large 3 year total shareholder return. This suggests momentum has been building as investors reassess Arcellx's prospects and risk profile.
If Arcellx has caught your attention, it can help to see what else is moving in related areas, including 35 healthcare AI stocks
So with Arcellx trading around US$114.33 after a sharp run and sitting near recent analyst targets, is the market overlooking its long term potential, or is the current price already baking in much of the future growth story?
Preferred Price to Book of 16.7x: Is It Justified?
Arcellx is trading on a P/B of 16.7x, which sits well above the broader US biotechs average and raises questions about how much optimism is already in the price.
The P/B ratio compares the company’s market value to its book value, or net assets. It is often used for early stage or unprofitable biotechs where earnings are still negative. A higher P/B can signal that investors are willing to pay a premium for the pipeline, partnership structure or expected future cash flows rather than the current balance sheet alone.
In Arcellx's case, the stock is described as expensive versus the US biotechs industry average P/B of 2.5x, yet it is flagged as good value against a peer group average P/B of 42x. That mix suggests the market is pricing in stronger prospects than the typical biotech name, but still at a discount to closer comparables that investors may see as more similar in terms of pipeline or stage of development.
The contrast between being expensive versus the sector and cheaper versus peers highlights how much the story depends on which comparison set you think matters most, and where P/B levels could eventually settle if sentiment shifts toward or away from that tighter peer group. See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-book of 16.7x (ABOUT RIGHT)
However, investors also need to weigh risks, including ongoing net losses of US$228.934m on modest US$22.286m revenue and the inherent uncertainty of clinical trial outcomes.
Find out about the key risks to this Arcellx narrative.
Another Angle: DCF Points To A Very Different Price
While the 16.7x P/B suggests Arcellx is already priced for strong expectations, the SWS DCF model paints a very different picture. With the shares at $114.33 and an estimated future cash flow value of $487.39, the model indicates Arcellx is trading at roughly a 76.5% discount to that estimate.
This kind of gap can signal either a potential opportunity if the cash flow assumptions hold up, or a warning that expectations in the model are more optimistic than the market is willing to accept today. Which side of that divide do you think is closer to reality, and what would need to change for the market to move?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Arcellx for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Does this mix of strong share price moves, premium valuation multiples and a wide DCF gap leave you excited or cautious? If you want to move quickly from headline impressions to your own evidence based view, it is worth looking at the detailed balance of risks and rewards that investors are already debating, starting with the 2 key rewards and 2 important warning signs
Ready For More Investment Ideas?
If Arcellx has sharpened your focus, now is the moment to widen your lens and see what other opportunities are already standing out on the Simply Wall St screener.
- Spot potential bargains early by scanning companies that combine quality with attractive pricing using the 49 high quality undervalued stocks.
- Prioritise resilience by checking out stocks that score well on stability in the 72 resilient stocks with low risk scores.
- Hunt for future standouts before the crowd by reviewing the screener containing 25 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com